Zobrazeno 1 - 8
of 8
pro vyhledávání: '"C J, Woyden"'
Autor:
C. J. Woyden, Roger M. Freidinger, Mark G. Bock, Duane R. Reiss, Joseph M. Pawluczyk, Michelle S. Kuo, Amy G. Quigley, Douglas J. Pettibone, Maribeth T. Guidotti, E V Lis, D. S. Perlow, Peter D. Williams
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 8:3081-3086
Structure-activity studies on the oxytocin antagonist 1 (L-371,257) have identified a new series of high affinity, receptor-selective OT antagonists in which the N-acetyl-4-piperidinyl ether terminus in 1 has been replaced with a 1-(aryl)ethoxy group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::765c00dce9dedfe799c42f855a73f496
https://doi.org/10.1016/s0960-894x(98)00568-x
https://doi.org/10.1016/s0960-894x(98)00568-x
Autor:
Steven N. Gallicchio, James P. Guare, C. J. Woyden, Duane R. Reiss, Carl F. Homnick, Roger M. Freidinger, S Vickers, Michelle S. Kuo, E V Lis, Stuart R. Michelson, Douglas J. Pettibone, Peter D. Williams, Joseph M. Pawluczyk, Erb Jm, Doug W. Hobbs, Ian M. Bell, Rita A. Halpin, David J. Mathre, Maribeth T. Guidotti
Publikováno v:
Journal of Medicinal Chemistry. 41:2146-2163
The previously reported oxytocin antagonist L-371,257 (2) has been modified at its acetylpiperidine terminus to incorporate various pyridine N-oxide groups. This modification has led to the identification of compounds with improved pharmacokinetics a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b74cfbae44800fb3afe7907b08d0fc3a
https://doi.org/10.1021/jm9800797
https://doi.org/10.1021/jm9800797
Autor:
C. J. Woyden, M. J. Novy, Mark G. Bock, Bradley V. Clineschmidt, B. E. Evans, E V Lis, Terry W. Schorn, K. L. Thompson, Peter K. S. Siegl, Douglas J. Pettibone, Duane R. Reiss, Peter D. Williams, Doug W. Hobbs, M. A. Cukierski, Maribeth T. Guidotti, Roger M. Freidinger, D. F. Veber, G. J. Haluska, M. J. Cook, M. J. Kaufman, S.-H. L. Chiu
Publikováno v:
Drug Development Research. 30:129-142
L-368,899 [1S-(-7,7-dimethyl-2-endo-(2S-amino-4-(methylsulfonyl)butyramido)-bicyclo(2.2.1)-heptan-1-yl)methanesulfonyl)-4-(2-methylphenyl)piperazine] was characterized in vitro and in vivo as a potent and selective, orally bioavailable oxytocin (OT)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2d543025961ee32823042a54971256b
https://doi.org/10.1002/ddr.430300305
https://doi.org/10.1002/ddr.430300305
Autor:
Douglas J. Pettibone, Peter D. Williams, C. J. Woyden, Roger M. Freidinger, Erb Jm, E V Lis, Duane R. Reiss, Bradley V. Clineschmidt, D. F. Veber, Maribeth T. Guidotti, Joseph M. Pawluczyk
Publikováno v:
ChemInform. 27
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8bacdd31854d5d30d21f04d2807f88e9
https://doi.org/10.1002/chin.199611203
https://doi.org/10.1002/chin.199611203
Autor:
C. J. Woyden, Stacey O'Malley, James C. Barrow, Roger M. Freidinger, Raymond S.L. Chang, Kristen L. Glass, Harold G. Selnick
Publikováno v:
ChemInform. 31
Several 1,3-diaminocyclopentane linked α 1a -receptor antagonists were prepared using a divergent chemical strategy that allows for rapid analysis of all stereochemical permutations for their effect on α 1 -receptor binding.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa9df6c02f5a952a9d9fe2d91270bc4a
https://doi.org/10.1002/chin.200047147
https://doi.org/10.1002/chin.200047147
Autor:
Michelle R. Levy, K.J. Stauffer, Roger M. Freidinger, E V Lis, Mark G. Bock, Stuart R. Michelson, Douglas J. Pettibone, D. S. Perlow, Christopher A. Salvatore, Marlene A. Jacobson, B. E. Evans, Joseph M. Pawluczyk, Amy G. Quigley, C. J. Woyden, Maribeth T. Guidotti, Peter D. Williams, Michelle S. Kuo, Steven N. Gallicchio, Duane R. Reiss
Publikováno v:
Bioorganicmedicinal chemistry letters. 9(9)
Structure-activity studies on the oxytocin antagonist 1 (L-371,257; Ki = 9.3 nM) have led to the identification of a related series of compounds containing an ortho-trifluoroethoxyphenylacetyl core which are orally bioavailable and have significantly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5060b712acd7d054079f1d505f8a7310
https://pubmed.ncbi.nlm.nih.gov/10340620
https://pubmed.ncbi.nlm.nih.gov/10340620
Autor:
D J, Pettibone, M, Guidotti, C M, Harrell, J R, Jasper, E V, Lis, J A, O'Brien, D R, Reiss, C J, Woyden, M G, Bock, B E, Evans
Publikováno v:
Advances in experimental medicine and biology. 395
From a targeted screening effort and medicinal chemistry program, L-368,899 was selected as the first orally-active oxytocin (OT) antagonist to enter clinical trials. In animal studies, L-368,899 was shown to be a potent and selective OT antagonist a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7bb48ac51478f41355019368a957d0e0
https://pubmed.ncbi.nlm.nih.gov/8714024
https://pubmed.ncbi.nlm.nih.gov/8714024
Autor:
D J, Pettibone, B V, Clineschmidt, M T, Kishel, E V, Lis, D R, Reiss, C J, Woyden, B E, Evans, R M, Freidinger, D F, Veber, M J, Cook
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 264(1)
L-366,509, a member of a novel class of nonpeptidyl compounds, has been characterized as an orally active oxytocin (OT) antagonist. L-366,509 exhibits a moderate binding affinity (K(i) values, 370-780 nM) for the rat, rhesus and human uterine OT rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7dbbeece56505f49c8185ebdd907b8ea
https://pubmed.ncbi.nlm.nih.gov/8423533
https://pubmed.ncbi.nlm.nih.gov/8423533